(RXST) Rxsight - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US78349D1072
Intraocular Lens, Light Delivery Device, Cataract Surgery
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 64.1% |
| Value at Risk 5%th | 93.7% |
| Relative Tail Risk | -11.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.93 |
| Alpha | -84.97 |
| CAGR/Max DD | 0.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.294 |
| Beta | 1.264 |
| Beta Downside | 2.318 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.66% |
| Mean DD | 31.86% |
| Median DD | 17.75% |
Description: RXST Rxsight October 23, 2025
RxSight, Inc. (NASDAQ:RXST) is a commercial-stage medical-technology firm that develops, manufactures, and sells a light-adjustable intraocular lens (LAL) system for cataract surgery in the United States.
The RxSight system pairs a photosensitive intraocular lens-capable of reshaping under patterned ultraviolet (UV) exposure-with an office-based UV light delivery device that allows surgeons to fine-tune a patient’s uncorrected visual acuity weeks after the procedure.
Key industry metrics that shape RxSight’s outlook include a U.S. cataract surgery market estimated at >$10 billion annually, a projected 5-6% CAGR for the premium intraocular-lens segment, and RxSight’s Q2 2024 revenue of $12.3 million with a cash runway extending into 2026. The company secured FDA clearance for its LAL in 2020 and has a distribution partnership with Alcon, which expands its reach into high-volume ophthalmology practices.
For a deeper, data-driven assessment of RxSight’s valuation and risk profile, consider reviewing the detailed analyst notes available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-35.7m TTM) > 0 and > 6% of Revenue (6% = 8.53m TTM) |
| FCFTA -0.07 (>2.0%) and ΔFCFTA 2.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 184.1% (prev 190.9%; Δ -6.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.06 (>3.0%) and CFO -18.7m > Net Income -35.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (41.0m) change vs 12m ago 2.96% (target <= -2.0% for YES) |
| Gross Margin 74.98% (prev 63.45%; Δ 11.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.91% (prev 44.57%; Δ 1.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1782 (EBITDA TTM -32.7m / Interest Expense TTM 20.0k) >= 6 (WARN >= 3) |
Altman Z'' -23.12
| (A) 0.85 = (Total Current Assets 283.9m - Total Current Liabilities 22.3m) / Total Assets 308.5m |
| (B) -2.11 = Retained Earnings (Balance) -651.9m / Total Assets 308.5m |
| warn (B) unusual magnitude: -2.11 — check mapping/units |
| (C) -0.12 = EBIT TTM -35.6m / Avg Total Assets 309.5m |
| (D) -20.02 = Book Value of Equity -651.8m / Total Liabilities 32.6m |
| Total Rating: -23.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.45
| 1. Piotroski 1.50pt |
| 2. FCF Yield -7.39% |
| 3. FCF Margin -15.62% |
| 4. Debt/Equity 0.04 |
| 5. Debt/Ebitda 0.55 |
| 6. ROIC - WACC (= -23.24)% |
| 7. RoE -12.82% |
| 8. Rev. Trend 90.64% |
| 9. EPS Trend 91.38% |
What is the price of RXST shares?
As of December 14, 2025, the stock is trading at USD 12.62 with a total of 587,324 shares traded.
Over the past week, the price has changed by -0.08%, over one month by +26.07%, over three months by +35.55% and over the past year by -64.84%.
Over the past week, the price has changed by -0.08%, over one month by +26.07%, over three months by +35.55% and over the past year by -64.84%.
Is RXST a buy, sell or hold?
Rxsight has received a consensus analysts rating of 3.73.
Therefor, it is recommend to hold RXST.
- Strong Buy: 4
- Buy: 2
- Hold: 3
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the RXST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | -20.8% |
| Analysts Target Price | 10 | -20.8% |
| ValueRay Target Price | 11.3 | -10.2% |
RXST Fundamental Data Overview December 10, 2025
Market Cap USD = 516.4m (516.4m USD * 1.0 USD.USD)
P/E Forward = 116.2791
P/S = 3.6346
P/B = 1.8817
Beta = 1.13
Revenue TTM = 142.1m USD
EBIT TTM = -35.6m USD
EBITDA TTM = -32.7m USD
Long Term Debt = 11.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.29m USD (from shortTermDebt, last quarter)
Debt = 11.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -18.1m USD (from netDebt column, last quarter)
Enterprise Value = 300.5m USD (516.4m + Debt 11.6m - CCE 227.5m)
Interest Coverage Ratio = -1782 (Ebit TTM -35.6m / Interest Expense TTM 20.0k)
FCF Yield = -7.39% (FCF TTM -22.2m / Enterprise Value 300.5m)
FCF Margin = -15.62% (FCF TTM -22.2m / Revenue TTM 142.1m)
Net Margin = -25.15% (Net Income TTM -35.7m / Revenue TTM 142.1m)
Gross Margin = 74.98% ((Revenue TTM 142.1m - Cost of Revenue TTM 35.6m) / Revenue TTM)
Gross Margin QoQ = 79.85% (prev 74.89%)
Tobins Q-Ratio = 0.97 (Enterprise Value 300.5m / Total Assets 308.5m)
Interest Expense / Debt = 0.03% (Interest Expense 4000 / Debt 11.6m)
Taxrate = -0.10% (negative due to tax credits) (10.0k / -9.81m)
NOPAT = -35.7m (EBIT -35.6m * (1 - -0.10%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 12.74 (Total Current Assets 283.9m / Total Current Liabilities 22.3m)
Debt / Equity = 0.04 (Debt 11.6m / totalStockholderEquity, last quarter 276.0m)
Debt / EBITDA = 0.55 (negative EBITDA) (Net Debt -18.1m / EBITDA -32.7m)
Debt / FCF = 0.81 (negative FCF - burning cash) (Net Debt -18.1m / FCF TTM -22.2m)
Total Stockholder Equity = 278.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.58% (Net Income -35.7m / Total Assets 308.5m)
RoE = -12.82% (Net Income TTM -35.7m / Total Stockholder Equity 278.6m)
RoCE = -12.28% (EBIT -35.6m / Capital Employed (Equity 278.6m + L.T.Debt 11.6m))
RoIC = -12.80% (negative operating profit) (NOPAT -35.7m / Invested Capital 278.6m)
WACC = 10.44% (E(516.4m)/V(528.0m) * Re(10.67%) + D(11.6m)/V(528.0m) * Rd(0.03%) * (1-Tc(-0.00)))
Discount Rate = 10.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.73%
Fair Price DCF = unknown (Cash Flow -22.2m)
EPS Correlation: 91.38 | EPS CAGR: 68.02% | SUE: 3.19 | # QB: 1
Revenue Correlation: 90.64 | Revenue CAGR: 40.73% | SUE: 1.08 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=+0.020 | Revisions Net=-2 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.48 | Chg30d=+0.104 | Revisions Net=+0 | Growth EPS=+13.6% | Growth Revenue=+4.2%
P/E Forward = 116.2791
P/S = 3.6346
P/B = 1.8817
Beta = 1.13
Revenue TTM = 142.1m USD
EBIT TTM = -35.6m USD
EBITDA TTM = -32.7m USD
Long Term Debt = 11.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.29m USD (from shortTermDebt, last quarter)
Debt = 11.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -18.1m USD (from netDebt column, last quarter)
Enterprise Value = 300.5m USD (516.4m + Debt 11.6m - CCE 227.5m)
Interest Coverage Ratio = -1782 (Ebit TTM -35.6m / Interest Expense TTM 20.0k)
FCF Yield = -7.39% (FCF TTM -22.2m / Enterprise Value 300.5m)
FCF Margin = -15.62% (FCF TTM -22.2m / Revenue TTM 142.1m)
Net Margin = -25.15% (Net Income TTM -35.7m / Revenue TTM 142.1m)
Gross Margin = 74.98% ((Revenue TTM 142.1m - Cost of Revenue TTM 35.6m) / Revenue TTM)
Gross Margin QoQ = 79.85% (prev 74.89%)
Tobins Q-Ratio = 0.97 (Enterprise Value 300.5m / Total Assets 308.5m)
Interest Expense / Debt = 0.03% (Interest Expense 4000 / Debt 11.6m)
Taxrate = -0.10% (negative due to tax credits) (10.0k / -9.81m)
NOPAT = -35.7m (EBIT -35.6m * (1 - -0.10%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 12.74 (Total Current Assets 283.9m / Total Current Liabilities 22.3m)
Debt / Equity = 0.04 (Debt 11.6m / totalStockholderEquity, last quarter 276.0m)
Debt / EBITDA = 0.55 (negative EBITDA) (Net Debt -18.1m / EBITDA -32.7m)
Debt / FCF = 0.81 (negative FCF - burning cash) (Net Debt -18.1m / FCF TTM -22.2m)
Total Stockholder Equity = 278.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.58% (Net Income -35.7m / Total Assets 308.5m)
RoE = -12.82% (Net Income TTM -35.7m / Total Stockholder Equity 278.6m)
RoCE = -12.28% (EBIT -35.6m / Capital Employed (Equity 278.6m + L.T.Debt 11.6m))
RoIC = -12.80% (negative operating profit) (NOPAT -35.7m / Invested Capital 278.6m)
WACC = 10.44% (E(516.4m)/V(528.0m) * Re(10.67%) + D(11.6m)/V(528.0m) * Rd(0.03%) * (1-Tc(-0.00)))
Discount Rate = 10.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.73%
Fair Price DCF = unknown (Cash Flow -22.2m)
EPS Correlation: 91.38 | EPS CAGR: 68.02% | SUE: 3.19 | # QB: 1
Revenue Correlation: 90.64 | Revenue CAGR: 40.73% | SUE: 1.08 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=+0.020 | Revisions Net=-2 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.48 | Chg30d=+0.104 | Revisions Net=+0 | Growth EPS=+13.6% | Growth Revenue=+4.2%
Additional Sources for RXST Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle